



Emerald Health Therapeutics' Partner STENOCARE Makes First Delivery of Medical Cannabis Oil to Swedish Patients

VANCOUVER, December 29, 2020 – Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV: EMH; OTCQX: EMHTF) today announced that its partner, STENOCARE A/S, completed its first shipment and delivery of Emerald medical cannabis oil to patients in Sweden.

In Sweden, several patients diagnosed with chronic nervous system pain, spasms and nausea from chemotherapy have via their doctor previously applied for a prescription for treatment with medical cannabis oil. Emerald and STENOCARE announced on September 8th approval from the Swedish Medicines Agency for STENOCARE to provide Emerald’s medical cannabis oil for treatment of Swedish patients. The Swedish and Canadian Health authorities have completed the required certificates and the first shipment of medical cannabis oil is now being delivered to the Swedish patients.

STENOCARE is a leading supplier of prescription-based medical cannabis products for patients’ treatment to help them improve quality of life. Emerald has an agreement to sell and supply its medical cannabis oil products to STENOCARE.

“We have been applying conventional treatment protocols to patients with neuropathic pain and find it relevant to supplement with medical cannabis. We will test how medical cannabis oil can help reduce pain, spasm and enable better mobility for patients with severe chronic pain related to cancer or nerve injuries,” said Niels V. Olsen, anesthesiologist, D.M.Sc., Pain and Psychiatry Centre Malmö.

“This is the first-ever full-spectrum medical cannabis oil product to be prescribed for treatment of Swedish patients. We look forward to following the efficacy of this treatment and to continue our strategy to enter new markets,” said Thomas Skovlund Schnegelsberg, CEO of STENOCARE.

“We commend STENOCARE on their success in opening a new market for medical cannabis oil and look forward to being a reliable supplier of high-quality medical cannabis oil products to serve the patients in need of these products,” said Riaz Bandali, President and CEO.

About Emerald Health Therapeutics

Emerald is committed to creating new consumer experiences with distinct recreational, medical and wellness-oriented cannabis products with an emphasis on innovation, science and product excellence.

Please visit www.emeraldhealth.ca for more information or contact:

Jenn Hepburn, Chief Financial Officer
(800) 757 3536 Ext. #5

Emerald Investor Relations
(800) 757 3536 Ext. #5
invest@emeraldhealth.ca

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Cautionary Note Regarding Forward-Looking Statements: Certain statements made in this press release that are not historical facts are forward-looking statements and are subject to important risks, uncertainties and assumptions, both general and specific, which give rise to the possibility that actual results or events could differ materially from our expectations expressed in or implied by such forward-looking statements.

We cannot guarantee that any forward-looking statement will materialize, and readers are cautioned not to place undue reliance on these forward-looking statements. These forward-looking statements involve risks and uncertainties related to, among other things, changes of law and regulations; changes of government; failure to obtain regulatory approvals or permits; failure to obtain necessary financing; results of production and sale activities; regulatory changes; changes in prices and costs of inputs; demand for products; changes in business strategy; as well as the risk factors described in Emerald's annual information form and other regulatory filings. The forward-looking statements contained in this press release represent our expectations as of the date hereof. Forward-looking statements are presented for the purpose of providing information about management's current expectations and plans and allowing investors and others to obtain a better understanding of our anticipated operating environment. Readers are cautioned that such information may not be appropriate for other purposes. Emerald undertakes no obligations to update or revise such statements to reflect new circumstances or unanticipated events as they occur, unless required by applicable law.